Literature DB >> 9537420

Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy.

C Minetti1, F Sotgia, C Bruno, P Scartezzini, P Broda, M Bado, E Masetti, M Mazzocco, A Egeo, M A Donati, D Volonte, F Galbiati, G Cordone, F D Bricarelli, M P Lisanti, F Zara.   

Abstract

Limb-girdle muscular dystrophy (LGMD) is a clinically and genetically heterogeneous group of myopathies, including autosomal dominant and recessive forms. To date, two autosomal dominant forms have been recognized: LGMD1A, linked to chromosome 5q, and LGMD1B, associated with cardiac defects and linked to chromosome 1q11-21. Here we describe eight patients from two different families with a new form of autosomal dominant LGMD, which we propose to call LGMD1C, associated with a severe deficiency of caveolin-3 in muscle fibres. Caveolin-3 (or M-caveolin) is the muscle-specific form of the caveolin protein family, which also includes caveolin-1 and -2. Caveolins are the principal protein components of caveolae (50-100 nm invaginations found in most cell types) which represent appendages or sub-compartments of plasma membranes. We localized the human caveolin-3 gene (CAV3) to chromosome 3p25 and identified two mutations in the gene: a missense mutation in the membrane-spanning region and a micro-deletion in the scaffolding domain. These mutations may interfere with caveolin-3 oligomerization and disrupt caveolae formation at the muscle cell plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9537420     DOI: 10.1038/ng0498-365

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  139 in total

Review 1.  Caveolins, liquid-ordered domains, and signal transduction.

Authors:  E J Smart; G A Graf; M A McNiven; W C Sessa; J A Engelman; P E Scherer; T Okamoto; M P Lisanti
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  RNAMotif, an RNA secondary structure definition and search algorithm.

Authors:  T J Macke; D J Ecker; R R Gutell; D Gautheret; D A Case; R Sampath
Journal:  Nucleic Acids Res       Date:  2001-11-15       Impact factor: 16.971

Review 3.  Caveolin-deficient mice: insights into caveolar function human disease.

Authors:  B Razani; M P Lisanti
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

4.  Ligand-independent activation of oestrogen receptor alpha by caveolin-1.

Authors:  A Schlegel; C Wang; R G Pestell; M P Lisanti
Journal:  Biochem J       Date:  2001-10-01       Impact factor: 3.857

5.  Palmitate-Induced Translocation of Caveolin-3 and Endothelial Nitric Oxide Synthase in Cardiomyocytes.

Authors:  Catherine J Knowles; Megan Dionne; Martina Cebova; Ilka M Pinz
Journal:  Online J Biol Sci       Date:  2011

Review 6.  Defining a new paradigm for human arrhythmia syndromes: phenotypic manifestations of gene mutations in ion channel- and transporter-associated proteins.

Authors:  Michael J Ackerman; Peter J Mohler
Journal:  Circ Res       Date:  2010-08-20       Impact factor: 17.367

Review 7.  Membrane Repair: Mechanisms and Pathophysiology.

Authors:  Sandra T Cooper; Paul L McNeil
Journal:  Physiol Rev       Date:  2015-10       Impact factor: 37.312

8.  Caveolin-3 associates with and affects the function of hyperpolarization-activated cyclic nucleotide-gated channel 4.

Authors:  Bin Ye; Ravi C Balijepalli; Jason D Foell; Stacie Kroboth; Qi Ye; Yu-Hong Luo; Nian-Qing Shi
Journal:  Biochemistry       Date:  2008-11-25       Impact factor: 3.162

9.  Expression levels of sarcolemmal membrane repair proteins following prolonged exercise training in mice.

Authors:  Jenna Alloush; Steve R Roof; Eric X Beck; Mark T Ziolo; Noah Weisleder
Journal:  Indian J Biochem Biophys       Date:  2013-10       Impact factor: 1.918

10.  Modulation of myoblast fusion by caveolin-3 in dystrophic skeletal muscle cells: implications for Duchenne muscular dystrophy and limb-girdle muscular dystrophy-1C.

Authors:  Daniela Volonte; Aaron J Peoples; Ferruccio Galbiati
Journal:  Mol Biol Cell       Date:  2003-08-07       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.